Advanced Viral Research Corp., of Yonkers, N.Y., was awarded U.S. Patent No. 6,303,153 titled ¿Preparation of a Therapeutic Composition.¿ The patent protects the preparation and composition of Product R, the nontoxic peptide-nucleic acid immunomodulator that the company developed.
Axiom Biotechnologies Inc., of San Diego, was issued U.S. Patent No. 6,287,758 for methods relating to measurements of cell membrane electric potential in single cells or in cell populations.
Collateral Therapeutics Inc., of San Diego, was issued U.S. Patent No. 6,306,830 titled ¿Gene Therapy for Congestive Heart Failure.¿ The patent relates to methods of in vivo gene transfer via nonsurgical administration for the potential treatment of congestive heart failure.
Genzyme Molecular Oncology, of Framingham, Mass., a division of Genzyme Corp., was issued U.S. Patent No. 6,306,640 for the discovery of novel, synthetic peptides and pharmaceutical compositions useful as therapeutic melanoma vaccines.
Hemispherx Biopharma Inc., of Philadelphia, was awarded a U.S. patent for an orally bioavailable inhibitor of HIV. The compound, designated ¿Oragen conjugate 33,¿ is a member of a new class of HIV inhibitors, which are designed to stop viral replication by preventing HIV from fusing to adjacent target cells in the body.
Imperial Cancer Research Technology Ltd., of London, was awarded U.S. Patent No. 6,287,854. The PTEN gene may be important for the treatment of cancer and hyperproliferative diseases, such as cardiovascular disease and rheumatoid arthritis. Introgen Therapeutics Inc., of Austin, Texas, is the exclusive licensee of this patent.
Maxim Pharmaceuticals Inc., of San Diego, received notice of allowance from the U.S. Patent and Trademark Office for Application No. 09/467,652 titled ¿Synthesis of Histamine Dihydrochloride.¿ The patent encompasses Maxim¿s novel synthetic method for the production of pharmaceutical-grade histamine dihydrochloride, the active agent in Ceplene. Maxim also was issued U.S. Patent No. 6,221,893 titled ¿Administration of Histamine for Therapeutic Purposes¿; U.S. Patent No. 6,242,473 titled ¿Treatment and Prevention of Reactive Oxygen Metabolite-Mediated Cellular Damage¿; and U.S. Patent No. 6,245,563 titled ¿Enhanced Activation of Natural Killer Cells Using an NK Cell Activator and Hydrogen Peroxide Scavenger or Inhibitor.¿
Nanogen Inc., of San Diego, was issued U.S. Patent No. 6,303,082 titled ¿Permeation Layer Attachment Chemistry and Method¿ and U.S. Patent No. 6,306,348 titled ¿Inorganic Permeation Layer for Microelectronic Devices.¿
NeoTherapeutics Inc., of Irvine, Calif., was awarded U.S. Patent No. 6,303,617 titled ¿Novel Serotonin-Like 9-Substituted Hypoxanthine and Methods of Use.¿ The new patent covers additional hypoxanthine-based compounds that have serotonin-like characteristics. NeoTherapeutics also was issued a U.S. patent titled ¿Carbon Monoxide Dependent Guanylyl Cyclase Modifiers and Methods of Use.¿ The patent covers the ability of Neotrofin and its analogues to treat certain conditions relating to oxidative stress, or tissue damage from free radicals.
Procyon Biopharma Inc., of Montreal, received a notice of allowance for the patent application No. 92,906,696.7-2107 for Fibrostat, a topical cream for the treatment of scars resulting from surgery or burns.